Inhibitor in Medical Technology
Navigation Links
Inhibitor in Medical Technology
... to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and ... coming months from our non-nucleoside polymerase inhibitor and protease inhibitor programs, we are closer to achieving our ultimate ...
... non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) ... with a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor as a preferred regimen for patients initiating ...
... Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in ... print edition in an article titled: A Selective inhibitor of the Immunoproteasome Subunit LMP7 Blocks ... is the first highly selective, small molecule inhibitor of the immunoproteasome. The proteasome is an ...
... activity as a highly selective and potent inhibitor of the proteasome for treatment of solid tumor ... for carfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. ... including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For ...
... "We've known that these CYP2D6 inhibitor drugs block the activation of tamoxifen ... far lower levels in the blood stream when CYP2D6 inhibitor drugs are present, and it is the first study to ... that patients used tamoxifen and a CYP2D6 inhibitor concurrently was 340 days. The analysis ...
... Failing Treatment Either with a VEGF Receptor inhibitor or after Treatment with both a VEGF Receptor inhibitor and an mTOR inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- ...
... dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not ... the first to evaluate the impact of a proton pump inhibitor on the amphetamine pharmacokinetics of VYVANSE ... drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the ...
... for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows: Time: ... SF1126 a vascular targeted PI3K Title: inhibitor administered twice weekly IV in patients with ... only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I ...
... 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) ... with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study ... Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer ....
... initiation of BPH, either D-3263, finasteride (an inhibitor of the enzyme 5-alpha-reductase) or a combination ... of the two. While finasteride is a known inhibitor of 5-alpha reductase, the enzyme that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may ...
... time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction ... (ITMN-191) R7227 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity, and has produced ...
... with HCV genotype 1. ITMN-191 is an HCV protease inhibitor being developed in collaboration with Roche. ... 2009. A Phase 1 trial of ITMN-191 and polymerase inhibitor R7128 (INFORM-1 Study) is currently underway. ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...
... ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV, and we ... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also ...
... care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting ... study, known as HCV SPRINT-1 (HCV Serine Protease inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated ... by week 4, therefore patients have the protease inhibitor added at a time when the backbone drug levels ...
... of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a ... lymphoma (NHL). This is the first Btk selective inhibitor to be tested in humans, and is Pharmacyclics' ... Fort Collins, CO About Pharmacyclics' Btk inhibitor Program PCI-32765 is currently targeted ...
... This includes a leading histone deacetylase inhibitor (PCI-24781) for multiple cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, ... colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) ...
... for use in HIV therapy is ritonavir, a protease inhibitor that has inherent antiviral activity. SPI-452 was designed to be a potent inhibitor of CYP3A enzymes with no antiviral activity and ... The first IND is for SPI- 256, an HIV protease inhibitor in phase 1 clinical development. The second ...
... (FDA) has granted priority review for Cinryze C1 inhibitor (human) as a treatment for acute attacks of ... subsequent HAE attacks. About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...
... trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their ... of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second ...
... CX-4945 represents the first potent and selective inhibitor of CK2 with a favorable safety profile and the ... About CX-4945, an oral CK2 protein kinase inhibitor CX-4945 is a first-in-class small molecule ... with the objective of creating a multifunctional inhibitor by targeting a single protein and affecting ...
... to suggest a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting ... seeing suggested survival benefit with aromatase inhibitor therapy for five years compared with tamoxifen ... both a head-to-head comparison of an aromatase inhibitor with tamoxifen during the first five years ...
... Oncology. Tasigna is a tyrosine kinase inhibitor approved for the treatment of adult Ph+ CML ... is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be ... to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. ...
... 1-Year Results of TOPS (Tyrosine Kinase inhibitor Optimization and Selectivity) Study (ASH ... Panobinostat (LBH589), a Novel Pan-Deacetylase inhibitor (DACi) Demonstrating Efficacy in Patients with ... is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6 and CYP2C9. Dosage of Gleevec ...
... characterization of its oral proteasome inhibitor known as PR-047. A complete list of the ... Poster II -- The Selective Proteasome inhibitor Carfilzomib is Well Tolerated in ... Characterization of PR-047, An Oral inhibitor of the 20S Proteasome (Abstract #3671) ...
... lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company ... to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company ... potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The ...
... of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically ... trial. About R7227 (ITMN-191) R7227 is an inhibitor of HCV NS3/4A protease activity, and has ... The hepatology portfolio includes HCV protease inhibitor ITMN-191 (R7227) in Phase 1b, a second-generation ...
... for Non-Nucleoside HCV Polymerase inhibitor Being Presented at AASLD SAN DIEGO, Nov. 1 ... Antiviral Agents that Include HCV Polymerase inhibitor ANA598 have the Potential to Overcome Viral ... synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside ...
... non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) ... with a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor as a preferred regimen for patients initiating ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... of the immune system, vicriviroc is an HIV entry inhibitor designed to prevent the virus from infecting ... therapy. Atazanavir is a product in the protease inhibitor (PI) class of HIV medications. Truvada is a ... in the nucleoside(tide) reverse transcriptase inhibitor (NRTI) class. The standard of care for ...... Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in ... print edition in an article titled: A Selective inhibitor of the Immunoproteasome Subunit LMP7 Blocks ... is the first highly selective, small molecule inhibitor of the immunoproteasome. The proteasome is an ...
... activity as a highly selective and potent inhibitor of the proteasome for treatment of solid tumor ... for carfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. ... including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For ...
... "We've known that these CYP2D6 inhibitor drugs block the activation of tamoxifen ... far lower levels in the blood stream when CYP2D6 inhibitor drugs are present, and it is the first study to ... that patients used tamoxifen and a CYP2D6 inhibitor concurrently was 340 days. The analysis ...
... Failing Treatment Either with a VEGF Receptor inhibitor or after Treatment with both a VEGF Receptor inhibitor and an mTOR inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- ...
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
... abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the 6th Annual C1 inhibitor Deficiency Workshop. Cinryze was approved ... approved, Cinryze would be the first C1 esterase inhibitor available for the acute treatment for this ...Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
... p.m. Min P, et al. Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by upregulating ... al. Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients ... AT-101 AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 ...... dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not ... the first to evaluate the impact of a proton pump inhibitor on the amphetamine pharmacokinetics of VYVANSE ... drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the ...
... for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows: Time: ... SF1126 a vascular targeted PI3K Title: inhibitor administered twice weekly IV in patients with ... only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I ...
... 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) ... with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study ... Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer ....
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
... first-in-class, orally available, PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the ... first-in-class, orally available, PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the ... a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the ...Isis and Collaborators Present New Research at the ATVB Annual Conference
... research programs, one on a direct antisense inhibitor of apoC-III, which may provide a promising new ... lower triglycerides, and a second on an antisense inhibitor to Factor XI, which has the potential to create a ... models. "The potential to add an apoC-III inhibitor in the near-term to our cardiovascular pipeline, ...... initiation of BPH, either D-3263, finasteride (an inhibitor of the enzyme 5-alpha-reductase) or a combination ... of the two. While finasteride is a known inhibitor of 5-alpha reductase, the enzyme that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may ...
... time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction ... (ITMN-191) R7227 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity, and has produced ...
... with HCV genotype 1. ITMN-191 is an HCV protease inhibitor being developed in collaboration with Roche. ... 2009. A Phase 1 trial of ITMN-191 and polymerase inhibitor R7128 (INFORM-1 Study) is currently underway. ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...
... ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV, and we ... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also ...
... care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting ... study, known as HCV SPRINT-1 (HCV Serine Protease inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated ... by week 4, therefore patients have the protease inhibitor added at a time when the backbone drug levels ...
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
... an orally active, novel, small molecule inhibitor of Pan HDAC enzymes, that is currently in Phase ... its innovative anti-cancer Pan HDAC inhibitor agents. "This alliance with Servier allows ... our unique and differentiated Pan HDAC inhibitor product outside of the United States in rapid ...Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
... description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is ... molecular target. CX-4945 is a potent, selective inhibitor of CK2 and modulates key survival pathways in ... 19, 2009: 8:00 AM CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the ...... of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a ... lymphoma (NHL). This is the first Btk selective inhibitor to be tested in humans, and is Pharmacyclics' ... Fort Collins, CO About Pharmacyclics' Btk inhibitor Program PCI-32765 is currently targeted ...
... This includes a leading histone deacetylase inhibitor (PCI-24781) for multiple cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, ... colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) ...
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
... (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for ... continues to exhibit promise as the only PTP1B inhibitor in development to simultaneously treat both type ... Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an ...... for use in HIV therapy is ritonavir, a protease inhibitor that has inherent antiviral activity. SPI-452 was designed to be a potent inhibitor of CYP3A enzymes with no antiviral activity and ... The first IND is for SPI- 256, an HIV protease inhibitor in phase 1 clinical development. The second ...
... (FDA) has granted priority review for Cinryze C1 inhibitor (human) as a treatment for acute attacks of ... subsequent HAE attacks. About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV and we ... been reported for any other non-nucleoside HCV inhibitor in a monotherapy study. Furthermore, the rate of ... agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The ...... trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their ... of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second ...
... CX-4945 represents the first potent and selective inhibitor of CK2 with a favorable safety profile and the ... About CX-4945, an oral CK2 protein kinase inhibitor CX-4945 is a first-in-class small molecule ... with the objective of creating a multifunctional inhibitor by targeting a single protein and affecting ...
... to suggest a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting ... seeing suggested survival benefit with aromatase inhibitor therapy for five years compared with tamoxifen ... both a head-to-head comparison of an aromatase inhibitor with tamoxifen during the first five years ...
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
... 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combination with ... study of ITMN-191 in combination with polymerase inhibitor R7128 (Roche/Pharmasset). INFORM-1 is the first ... portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...... Oncology. Tasigna is a tyrosine kinase inhibitor approved for the treatment of adult Ph+ CML ... is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be ... to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. ...
... 1-Year Results of TOPS (Tyrosine Kinase inhibitor Optimization and Selectivity) Study (ASH ... Panobinostat (LBH589), a Novel Pan-Deacetylase inhibitor (DACi) Demonstrating Efficacy in Patients with ... is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6 and CYP2C9. Dosage of Gleevec ...
... characterization of its oral proteasome inhibitor known as PR-047. A complete list of the ... Poster II -- The Selective Proteasome inhibitor Carfilzomib is Well Tolerated in ... Characterization of PR-047, An Oral inhibitor of the 20S Proteasome (Abstract #3671) ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... and Japan); Boceprevir, an oral protease inhibitor for treating hepatitis C with peginterferon and ... SVR; in addition, a next-generation protease inhibitor in Phase II for treating hepatitis C was ... Two projects for Alzheimer's -- a beta secretase inhibitor and a gamma secretase inhibitor; and A ...... lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company ... to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company ... potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The ...
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
... of their family members." About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ... in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 ...Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
... New data on PREZISTA(R) (darunavir), a protease inhibitor from Tibotec, will be presented at the Ninth ... reverse transcriptase inhibitor (NNRTI). The company continues to research ... in combination with a boosted protease inhibitor and other antiretroviral medicinal products, ...... of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically ... trial. About R7227 (ITMN-191) R7227 is an inhibitor of HCV NS3/4A protease activity, and has ... The hepatology portfolio includes HCV protease inhibitor ITMN-191 (R7227) in Phase 1b, a second-generation ...
... for Non-Nucleoside HCV Polymerase inhibitor Being Presented at AASLD SAN DIEGO, Nov. 1 ... Antiviral Agents that Include HCV Polymerase inhibitor ANA598 have the Potential to Overcome Viral ... synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside ...
Other ContentsflexorflexorflexorflowerflowerflowercytometrycytometrycytometrymodelmodelmodelmodelmodelmodelmodelmodelmodelmodelfluidfluidfluidfluidfluidfluidfluidfluidfluidfolioseOther Tags
(Date:12/3/2009)...n it comes to investment in energy efficient techn...ences Research Council (EPSRC) Chief Executive Dav...and engineering research has already brought us fu...but more investment is needed to develop the capab...ur carbon emission targets by 2020 and limit the i...
(Date:12/2/2009)...results strengthen the evidence that people who sm...increased risk for developing colorectal cancer, e...This provides one more reason not to smoke, or to ...ael J. Thun, M.D., M.S., vice president emeritus, ...ican Cancer Society. "Colorectal cancer should be ...
(Date:12/2/2009)... a cancer-free status did not prompt people partic...) lung-cancer screening program to pick up their c...ished in Cancer Epidemiology, Biomarkers & Preven...ancer Research. The December issue contains a spec...gate widespread concern in the lung screening comm...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Statins May Worsen Fatigue in Heart Failure Patients 60606 1Statins May Worsen Fatigue in Heart Failure Patients 60606 2Statins May Worsen Fatigue in Heart Failure Patients 60606 3Sun or shade 3A Pecan leaves photosynthetic light response evaluated 10611 1Sun or shade 3A Pecan leaves photosynthetic light response evaluated 10611 2A Breast Cancer Test That Saves Lives 60601 1A Breast Cancer Test That Saves Lives 60601 2A Breast Cancer Test That Saves Lives 60601 3(Date:12/4/2009)...ether procedure done immediately or 3 weeks later,...ay News) -- Timing of surgical repair or reconstru...ffect patient outcome, a new study has found. ,...atic knee dislocations that can occur in high-impa...ime to perform surgery to repair these injuries ha...
(Date:12/4/2009)...N, Dec. 4 Substantial progress has...e community,s ability to diagnose and treat epilep...ilepsy management has not reached most of the 50 m...the nearly three million people in the United Stat...n C. Schachter, M.D., president of the American Ep...
(Date:12/4/2009)... virus will come back during winter isn,t known, C...News) -- The number of states reporting widespread... -- to 25 from a high of 48 just two weeks ago, a ...the supply of H1N1 swine flu vaccine continues to ....S. Centers for Disease Control and Prevention, sa...
(Date:12/4/2009)...edge of risks, many hesitate to take breast cancer...ealthDay News) -- Worries about side effects are a... at high risk for breast cancer are willing to tak... study finds. , In an effort to inform women ab...rs at the University of Michigan Comprehensive Can...
(Date:12/4/2009)...DISON, Wis., Dec. 4 When... Wisconsin Department of Health Services needed to...than ever before. Join Sonic Foundry, Inc. (Nasd... media webcasting and knowledge management, for a ...n Department of Health Services, will share how in...
Breaking Medicine News(10 mins):Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Swine Flu Continues to Wane 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3[0] Timing of Multiple-Ligament Knee Surgery May Not Matter[0] Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care[0] Swine Flu Continues to Wane [0] High-Risk Women May Often Avoid Using Tamoxifen [0] Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications
JavelinTrophosAllosAnadysMilliporeModigeneAvalonAmylinConjuChemBiodelNeoprobeCethromycinOrexigenPharmexa
Other Tagsrecalling 2victory 2rewarding 2predicted 2predicted 3predicted 4predicted 5predicted 6predicted 7predicted 8predicted 9
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |